- Home
- LTRN vs SCLX Comparison
LTRN vs SCLX Comparison
Compare LTRN & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- SCLX
- Stock Information
- Founded
- LTRN 2013
- SCLX 2011
- Country
- LTRN United States
- SCLX United States
- Employees
- LTRN N/A
- SCLX N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- SCLX Health Care
- Exchange
- LTRN Nasdaq
- SCLX Nasdaq
- Market Cap
- LTRN 36.0M
- SCLX 34.3M
- IPO Year
- LTRN 2020
- SCLX N/A
- Fundamental
- Price
- LTRN $3.74
- SCLX $6.46
- Analyst Decision
- LTRN Strong Buy
- SCLX Strong Buy
- Analyst Count
- LTRN 1
- SCLX 3
- Target Price
- LTRN $25.00
- SCLX $367.50
- AVG Volume (30 Days)
- LTRN 281.3K
- SCLX 93.4K
- Earning Date
- LTRN 08-07-2025
- SCLX 08-12-2025
- Dividend Yield
- LTRN N/A
- SCLX N/A
- EPS Growth
- LTRN N/A
- SCLX N/A
- EPS
- LTRN N/A
- SCLX N/A
- Revenue
- LTRN N/A
- SCLX $50,710,000.00
- Revenue This Year
- LTRN N/A
- SCLX $107.00
- Revenue Next Year
- LTRN N/A
- SCLX $82.52
- P/E Ratio
- LTRN N/A
- SCLX N/A
- Revenue Growth
- LTRN N/A
- SCLX 7.79
- 52 Week Low
- LTRN $2.55
- SCLX $3.60
- 52 Week High
- LTRN $6.12
- SCLX $73.50
- Technical
- Relative Strength Index (RSI)
- LTRN 63.62
- SCLX 61.59
- Support Level
- LTRN $3.21
- SCLX $6.00
- Resistance Level
- LTRN $3.75
- SCLX $6.76
- Average True Range (ATR)
- LTRN 0.24
- SCLX 0.45
- MACD
- LTRN 0.07
- SCLX 0.10
- Stochastic Oscillator
- LTRN 98.65
- SCLX 86.55
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.